Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.

Noopur Raje, MD., Paul Richardson, M.D., Parameswaran N Hari, MD, Anuj Mahindra, Sarah Kaster, BS, Christine Connolly, Linda Rivera, Gaurav Chetri, Sarah Dean, Paulette Jacobs, Ayman Saad, MD, Jacob Laubach, Irene M. Ghobrial, M.D., Robert L Schlossman, M.D., Ph.D., Jennifer Adams, Wendy Makrides, Edie Weller, PhD, Nikhil Munshi, M.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3856.

https://doi.org/10.1182/blood.V114.22.3856.3856

Published: 2009

Journal Articles

Molecular Profiling of Extramedullary and Medullary Plasmacytomas

Gabriela Motyckova, M.D., Ph.D., Aliyah Rahemtullah, M.D., Nileshwari Vaghela, M.S., Sonia Vallet, M.D., Adam Ackerman, Siddhartha Mukherjee, M.D., Ph.D., Samantha Pozzi, M.D., Loredana Santo, Ph.D., Diana Cirstea, M.D., Christiana Toomey, Ephraim P. Hochberg, M.D., Paola Dal Cin, Ph.D., Scott Rodig, M.D., Ph.D., Teru Hideshima, M.D., Ph.D., Kenneth C Anderson, M.D., Nikhil Munshi, M.D., Noopur Raje, M.D.

Blood (2008) 112 (11): 5111.

https://doi.org/10.1182/blood.V112.11.5111.5111

Published: 2008

Journal Articles

Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application.

Dharminder Chauhan, PhD, Mohan Brahmandam, M.S., Ajita Singh, Ph.D, Giada Bianchi, M.D., Klaus Podar, M.D., Ruben Carrasco, Ph.D, Paul Richardson, M.D., Nikhil Munshi, M.D., Kenneth C. Anderson, M.D.

Blood (2007) 110 (11): 3507.

https://doi.org/10.1182/blood.V110.11.3507.3507

Published: 2007

Journal Articles

Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma.

Dharminder Chauhan, PhD, Ajita Singh, Ph.D, Mohan Brahmandam, M.S, Klaus Podar, Ph.D, Teru Hideshima, M.D., Robert Schlossman, M.D., Paul Richardson, M.D., Nikhil Munshi, M.D., Michael Palladino, Ph.D, Kenneth C. Anderson, M.D.

Blood (2007) 110 (11): 2524.

https://doi.org/10.1182/blood.V110.11.2524.2524

Published: 2007

Journal Articles

Acquisition of New In Vivo Genomic Change over Time in Multiple Myeloma.

Yu-Tzu Tai, PhD, Leutz Buon, M.S., Benjamin King, B.S., Cheng Li Cheng Li, Ph.D., Peter Burger Peter Burger, B.S., Xian-Feng Li, M.S., Weihua Song, M.D., Robert Schlossman, M.D., Paul Richardson, M.D., Kenneth C. Anderson, M.D., Nikhil Munshi, M.D.

Blood (2007) 110 (11): 2481.

https://doi.org/10.1182/blood.V110.11.2481.2481

Published: 2007

Journal Articles

Bcl-2, Mcl-1 and p53 Expression Confer Sensitivity to Bcl-2 Inhibitor ABT-737 in Multiple Myeloma.

Dharminder Chauhan, PhD, Mohan Brahmandam, M.S, Teru Hideshima, Ph.D, Klaus Podar, Ph.D, Nikhil Munshi, M.D, Noopur Raje, M.D, Kenneth C. Anderson, M.D

Blood (2006) 108 (11): 3474.

https://doi.org/10.1182/blood.V108.11.3474.3474

Published: 2006

Journal Articles

p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma.

Kenji Ishitsuka, MD, PhD, Teru Hideshima, M.D., Ph.D., Paola Neri, M.D., Ph.D., Sonia Vallet, M.D., Ph.D., Norihiko Shiraishi, Ph.D., Noopur Raje, M.D., Zhenxin Shen, M.D., Ph.D., Tanyel Kiziltepe, Ph.D., Enrique M. Ocio, M.D., Ph.D., Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D., Nikhil Munshi, M.D., Robert M. Campbell, Ph.D., Alfonso De Dios, Ph.D., Chuan Shih, Ph.D., James J. Starling, Ph.D., Kazuo Tamura, M.D., Ph.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 5042.

https://doi.org/10.1182/blood.V108.11.5042.5042

Published: 2006

Journal Articles

Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.

Dharminder Chauhan, PhD, Laurence Catley, M.D, Mugdha Velankar, M.S, Anthony Letai, M.D, Teru Hideshima, Ph.D, Klaus Podar, M.D, Hiroshi Yasui, M.D, Nicholas Mitsiades, M.D, Constantine Mitsiades, M.D, Yu-Tzu Tai, Ph.D, Noopur Raje, M.D, Nikhil Munshi, M.D, Michael A. Palladino, Ph.D, Kenneth C. Anderson, M.D

Blood (2005) 106 (11): 3378.

https://doi.org/10.1182/blood.V106.11.3378.3378

Published: 2005

Journal Articles

Hsp90 Is Critical for the Regulation of Human T Lymphocytes and NK Cell Phenotype and Function.

Jooeun Bae, PhD, Constantine Mitsiades, M.D., Rao Prabhala Prabhala, PhD, Tai Yu-Tzu, PhD, Jeff Martinson, BS, Steven Hartson, PhD, Teru Hideshima, PhD, Lawrence Catley, M.D., Xianfeng Li, BS, Ramesh Babu Batchu, PhD, Robert Bertheau, BS, Shammas Masood, PhD, Sushima Samala, M.S., Jeff Miller, PhD, Kenneth Anderson, M.D., Nikhil Munshi, M.D.

Blood (2005) 106 (11): 3464.

https://doi.org/10.1182/blood.V106.11.3464.3464

Published: 2005

Journal Articles

Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).

Dharminder Chauhan, Ph.D, Guilan Li, M.S, Teru Hideshima, Ph.D, Klaus Podar, Ph.D, Pierfrancesco Tassone, M.D., Paola E. Neri, M.D., Constantine Mitsiades, Ph.D, Nicholas Mitsiades, M.D., Noopur Raje, M.D., Shaji Kumar, M.D., Robert Schlossman, M.D., Sushil Sharma, M.D., Nikhil Munshi, M.D., Leigh Zawel, Ph.D, Kenneth C. Anderson, M.D.

Blood (2004) 104 (11): 764.

https://doi.org/10.1182/blood.V104.11.764.764

Published: 2004

Journal Articles

A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.

Dharminder Chauhan, Ph.D, Guilan Li, M.S, Klaus Podar, Ph.D, Teru Hideshima, Ph.D, Reshma Shrigarpure, Ph.D, Laurence Catley, M.D, Constantine Mitsiades, Ph.D, Nikhil Munshi, M.D, Robert Sclossman, M.D, Rena Bahjat, Ph.D, Saskia Neuteboom, M.D., Paul Richardson, M.D, Michael Palladino, Ph.D, Kenneth C. Anderson, M.D

Blood (2004) 104 (11): 2405.

https://doi.org/10.1182/blood.V104.11.2405.2405

Published: 2004

NARROW

An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.

Molecular Profiling of Extramedullary and Medullary Plasmacytomas

Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application.

Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma.

Acquisition of New In Vivo Genomic Change over Time in Multiple Myeloma.

Bcl-2, Mcl-1 and p53 Expression Confer Sensitivity to Bcl-2 Inhibitor ABT-737 in Multiple Myeloma.

p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma.

Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.

Hsp90 Is Critical for the Regulation of Human T Lymphocytes and NK Cell Phenotype and Function.

Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).

A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only